Basal Cell Carcinoma in Basal Cell Nevus SyndromePhase 1/2NCT03208296
Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
A Phase 1/2 study testing ASN-002 in people with Basal Cell Carcinoma in Basal Cell Nevus Syndrome, run by Ascend Biopharmaceuticals Ltd at 1 site in United States.
Trial summary
The primary objective is to confirm the safety of treating multiple BCCs once weekly x 3 weeks in individuals with Basal Cell Nevus Syndrome (BCNS). The secondary objectives of the study are to obtain preliminary data on the effectiveness of ASN-002 in the treatment of BCCs in individuals with Basal Cell Nevus… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Basal Cell Carcinoma in Basal Cell Nevus Syndrome
- What is being tested?
- ASN-002
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 24 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Dec 2017to 31 Mar 2025
- Phase
- Phase 1/2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Must satisfy established criteria for the diagnosis of BCNS (Section 1.1.2, Table 1).
- Must have at least 4 target lesions, clinically consistent with BCC.
- Up to 6 target lesions, including each of the 3 or 4 to-be-injected lesions and 1 or 2 non-injected lesions must be biopsied.
- At least 3 target lesions, 2 to be injected and one to be non-injected, must be biopsy proven BCC per criteria in Synopsis Table 3: Modified Criteria for Low Risk BCC in BCNS Patients
- Removal of < 25% of the area of the tumor by initial biopsy performed within 12 weeks before screening visit. A 2mm punch biopsy is recommended for histological confirmation of BCC.
- Screening laboratory values as follows:
Show all 16Show fewer
- Neutrophil count > 1500/mm3
- Hemoglobin > 10 g/dL
- Platelet count > 100,000/mm3
- Total bilirubin < 1.5 X upper limit of normal (ULN), except in the case of known Gilbert's syndrome
- Aspartate transaminase (AST), alanine transaminase (ALT) or alkaline phosphatase (ALP) < 1.5X ULN
- Creatinine < 1.5 X upper limit of normal (ULN)
- 18 years of age or older at Screening visit.
- Infertile, postmenopausal, surgically sterile or using acceptable and highly effective birth control methods for the duration of the study and for 3 months after last administration of ASN-002.
- Written informed consent prior to initiation of study-specified procedures.
- Able and willing to comply with all study requirements, including surgical removal of tumor/tumor sites as required by the study.
Who cannot join
- Target tumor biopsy shows evidence of:
- micronodular features,
- squamous metaplasia,
- sclerosing BCC,
- morpheic BCC, or
- peri-neural involvement.
Show all 19Show fewer
- cystic BCC
- Eastern Cooperative Oncology Group (ECOG) performance status > 2.
- Known or suspected metastatic disease.
- Female participants must be non-lactating and non-pregnant.
- Clinically active or uncontrolled skin disease that would interfere with evaluation of the area surrounding the target tumor (e.g. eczema, unstable psoriasis, xeroderma pigmentosa).
- Known history of sensitivity to any of the ingredients in ASN-002.
- Immunocompromised (e.g. known hepatitis B or C or HIV infection) or is receiving or is expected to receive an immunomodulating agent (including immunosuppressive agents, cytotoxic drugs, biological agents, immunoglobulins, interferon or other immune or cytokine-based therapies; regular use of inhaled or oral corticosteroids at doses higher than replacement doses is an exclusion criterion).
- Treatment with psoralen plus UVA or UVB therapy within 3 months of screening and agrees not to receive such treatment until excision site is confirmed to be well healed at the post-surgery study visits
- Prior systemic or local treatment for target tumors.
- History of immunological disorder, severe allergic reaction, moderate or severe asthma or known history of anaphylaxis or any other serious adverse reactions to any medication.
- Any serious or active medical or psychiatric illness or recreational or therapeutic drug or alcohol use that, in the opinion of the Investigator, would interfere with treatment, assessment or compliance with the protocol, or subject safety.
- Any experimental or investigational agents within 1 month of first injection.
- Any prior exposure to TG1041, TG1042 (ASN-002), any other adenoviral-based experimental agent within 5 months prior to screening visit.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Phase 1b/2a Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
The primary objective is to confirm the safety of treating multiple BCCs once weekly x 3 weeks in individuals with Basal Cell Nevus Syndrome (BCNS).
The secondary objectives of the study are to obtain preliminary data on the effectiveness of ASN-002 in the treatment of BCCs in individuals with Basal Cell Nevus Syndrome (BCNS) by
- evaluating the histological clearance of BCCs in patients with BCNS, and
- assessing the clinical changes of BCCs after treatment with ASN-002, and
- assessing the systemic effect of ASN-002 by determining response in non-injected lesions
- assess the safety and clinical changes after a second cycle of ASN-002 injections
Read the detailed description
Methodology:
Patients with BCNS who meet the Eligibility Requirements below will be studied. After informed consent is obtained and baseline evaluation, each lesion to be injected will receive ASN-002 once weekly x 3 weeks. Subjects will be premedicated with acetaminophen, 1000mg, 30 minutes prior to injection and continue 650mg, four times/day for two days after injection. Evaluation for toxicity and safety will be performed at 1, 2, 3 and 4 months after the first injection. All target lesions will be excised at 6 months and the subject evaluated for healing one month later.
Subjects with 5 or more lesions will be entered into Cohort A and will receive 1.0 x 1011 vp/injection into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3, i.e. a total dose of 4.0 x 1011 vp on each day of injections. If one subject in this cohort experiences Grade 3 or greater local or systemic toxicities by week 4, three additional subjects will be accrued to this cohort. If none of the first 3 subjects or no more than one of the six subjects in the expanded cohort experiences Grade 3 or greater local or systemic toxicities by week 4, the total dose of 4.0 x 1011 vp/day will be accepted for further clinical assessment. All four injected lesions and 1 or 2 non-injected lesions will be excised after 6 months.
Cohort B will be open for accrual to patients with 4 or more lesions once Cohort A is accepted for further clinical assessment or if Cohort A has >1/6 Grade 3 AEs. Subjects in Cohort B will receive 1.5 or 1.0 x 1011 vp/injection into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3, i.e. a total dose of 4.5 or 3.0 x 1011 vp on each day of injections as outlined in Synopsis Table 2 below. If one subject in this cohort experiences Grade 3 or greater local or systemic toxicities by week 4, three additional subjects will be accrued to this cohort. If none of the first 3 subjects or no more than one of the six subjects in the expanded Cohort B1.5 or B1.0 experiences Grade 3 or greater local or systemic toxicities by week 4, that total dose of 4.5 or 3.0 x 1011 vp/day will be accepted for further clinical assessment. All three injected lesions and 1-2 non-injected lesions will be excised after 6 months.
Cohort C may be designed based on the results observed in Cohorts A and B with the agreement of the Protocol Steering Committee. If a total dose >4.5 x 1011 vp/day of injection ASN-002 on any single day or more than 3 weekly injections are to be administered, a formal amendment to the Protocol must be approved before accrual to Cohort C is permitted.
Each cohort will be assessed for safety, dose escalation and possible cohort expansion as described above. The week 4 assessment of toxicity and apparent efficacy of the first 3 subjects in each cohort will be used to determine the need to increase the size of that cohort to 6 subjects. Cohorts will be assessed clinically at 1, 2, 3 and 4 months. Treated tumors will be resected at 6 months, based on observations in the ongoing Australia trial study that inflammation persisting at 16 weeks could not be reliably distinguished from residual tumor. The 1st and 3rd secondary endpoints, histological clearance of injected and non-injected lesions, will be assessed by the Pathology Department of each clinical site. Representative slides will be submitted for possible central review to be performed at the discretion of Ascend. Each participant will also be seen one month after tumor resection to assess healing and post-surgical results Each subject may be evaluated on the 7 month visit for a second cycle of 3 weekly ASN-002 injections into new or previously untreated BCC lesions at a dose accepted for further clinical assessment. Subjects who receive a second cycle will be followed for 6 months as before, but lesion excision will be at the discretion of the investigator.
In the event study subjects in any Cohort do not proceed to histological confirmation of response per protocol, they may be replaced as long as the reason for not proceeding to histological confirmation of response per protocol was not investigational product related adverse events and so long as the Protocol Steering Committee concurs with the Sponsor that no limiting safety issues have been identified.
Depending on results, and at the discretion of the Sponsor and the Protocol Steering Committee, one Cohort may be expanded to a total of 24 subjects so long as no more than one of six subjects already included at that dose and schedule of ASN-002 experienced Grade 3 or greater local or systemic toxicities. The selection of the cohort to be expanded will be based on favorable response data from the subjects already included at that dose and schedule of ASN-002,
- Being tested
- ASN-002
- Keywords
- Basal Cell Nevus Syndrome, Basal Cell Carcinoma
- Medical subject headings
- Basal Cell Nevus Syndrome, Carcinoma, Basal Cell
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ASN-002Biological
ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
| Study group | Role | What they receive |
|---|---|---|
| Cohort A | Experimental | Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3 Receives: Biological: ASN-002 |
| Cohort B 1.5 | Experimental | Subjects with 4 or more lesions will receive 1.5 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3 Receives: Biological: ASN-002 |
| Cohort B 1.0 | Experimental | Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3 Receives: Biological: ASN-002 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety of ASN-002 will be studied in terms of AEs reported in individuals with Basal Cell Nevus Syndrome (BCNS) receiving ASN-002 using CTCAE 4.03.
Clinical safety will assessed in terms of changes in vital signs, AEs, serious AEs (SAEs), laboratory abnormalities and withdrawals from study. Local skin and injection site reactions will be assessed in detail scoring erythema, ulceration, pain and overall severity as none, mild, moderate or severe using protocol-specific modifications of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
Measured: The assessment will be conducted at every visit after first dose, week1, week2, week 3, Months1, 2, 3, 4 and at Month 6.
Secondary outcomes (6)
Treatment efficacy in term of percentage of histological cure of BCC lesions at 6 months
At the end of the study, BCC lesions will be excised and studied under microscope to study the complete cure of BCC i.e. histological clearance
Measured: 6 months from baseline
Clinical changes in BCCs after treatment with ASN-002 in- terms of change in lesion size (mm)
The BCC lesions will be measured in mm at baseline, after first dose at Months1, 2, 3, 4 and at Month 6 to study the change in lesion size and clinical response.
Measured: 6 months from baseline.
The systemic effect of ASN-002 will be assessed for non-injected lesions by studying the change in lesion size from baseline to end of the study.
The non-injected BCC lesions will be measured in mm at baseline, after first dose at Months1, 2, 3, 4 and at Month 6 to study the change in lesion size and clinical response.
Measured: 6 months from baseline
The safety in terms of the AEs reported (using CTCAE 4.03) after 6 months from first dose in retreatment cycle
Clinical safety will assessed in terms of changes in vital signs, AEs, serious AEs (SAEs), laboratory abnormalities and withdrawals from study. Local skin and injection site reactions will be assessed in detail scoring erythema, ulceration, pain and overall severity as none, mild, moderate or severe using protocol-specific modifications of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
Measured: 6 months
The systemic effect of ASN-002 will be assessed for non-injected lesions by studying the rate of histological clearance after 6 months of first dose.
At the end of the study, BCC lesions will be excised and studied under microscope to study the complete cure of BCC i.e. histological clearance
Measured: 6 months from baseline
The efficacy will be assessed in terms of change in lesion size (mm) after 6 months from first dose in retreatment cycle
The change in lesions size in mm will be studied after 6 months from first dose in retreatment cycle.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jul 2017
- Study start1 Dec 2017
- Primary completion31 Dec 2024 (estimated)
- Study completion31 Mar 2025 (estimated)
Why it stopped: Study did not start. Another protocol is being developed. Recruitment on hold.
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Basal Cell Carcinoma in Basal Cell Nevus SyndromeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Model description
- This is a dose escalation study to determine the safety and efficacy of ASN-002 in treatment of BCCs in BCNS patients.
- Masking
- None (open label)
- Enrolment
- 24 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ascend Biopharmaceuticals Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clement Leong, Study chair, Ascend Biopharmaceuticals LtdAnna Bar, Principal investigator, Oregon Health and Science University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03208296
- Sponsor's protocol ID
- ASN-002-002
- Status last verified
- Jan 2023
- First submitted
- 29 Jun 2017
- Last updated
- 6 Feb 2023
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The decision will be taken in due course of time.
Study at a glance
From the registry record, last updated by the sponsor on 6 Feb 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 1b/2a Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)
- ClinicalTrials.gov ID
- NCT03208296
- Acronym / sponsor ID
- ASN-002-002
- Keywords
- Basal Cell Nevus Syndrome, Basal Cell Carcinoma
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- SuspendedReason stopped: Study did not start. Another protocol is being developed. Recruitment on hold.
- Enrolment
- 24 participants (estimated)
- Lead sponsor
- Ascend Biopharmaceuticals LtdIndustry (pharma, biotech, devices)
- Study start
- 1 Dec 2017 (actual)
- Primary completion
- 31 Dec 2024 (estimated)
- Study completion
- 31 Mar 2025 (estimated)
- First posted
- 5 Jul 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective is to confirm the safety of treating multiple BCCs once weekly x 3 weeks in individuals with Basal Cell Nevus Syndrome (BCNS).
The secondary objectives of the study are to obtain preliminary data on the effectiveness of ASN-002 in the treatment of BCCs in individuals with Basal Cell Nevus Syndrome (BCNS) by
- evaluating the histological clearance of BCCs in patients with BCNS, and
- assessing the clinical changes of BCCs after treatment with ASN-002, and
- assessing the systemic effect of ASN-002 by determining response in non-injected lesions
- assess the safety and clinical changes after a second cycle of ASN-002 injections
Detailed description
Methodology:
Patients with BCNS who meet the Eligibility Requirements below will be studied. After informed consent is obtained and baseline evaluation, each lesion to be injected will receive ASN-002 once weekly x 3 weeks. Subjects will be premedicated with acetaminophen, 1000mg, 30 minutes prior to injection and continue 650mg, four times/day for two days after injection. Evaluation for toxicity and safety will be performed at 1, 2, 3 and 4 months after the first injection. All target lesions will be excised at 6 months and the subject evaluated for healing one month later.
Subjects with 5 or more lesions will be entered into Cohort A and will receive 1.0 x 1011 vp/injection into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3, i.e. a total dose of 4.0 x 1011 vp on each day of injections. If one subject in this cohort experiences Grade 3 or greater local or systemic toxicities by week 4, three additional subjects will be accrued to this cohort. If none of the first 3 subjects or no more than one of the six subjects in the expanded cohort experiences Grade 3 or greater local or systemic toxicities by week 4, the total dose of 4.0 x 1011 vp/day will be accepted for further clinical assessment. All four injected lesions and 1 or 2 non-injected lesions will be excised after 6 months.
Cohort B will be open for accrual to patients with 4 or more lesions once Cohort A is accepted for further clinical assessment or if Cohort A has >1/6 Grade 3 AEs. Subjects in Cohort B will receive 1.5 or 1.0 x 1011 vp/injection into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3, i.e. a total dose of 4.5 or 3.0 x 1011 vp on each day of injections as outlined in Synopsis Table 2 below. If one subject in this cohort experiences Grade 3 or greater local or systemic toxicities by week 4, three additional subjects will be accrued to this cohort. If none of the first 3 subjects or no more than one of the six subjects in the expanded Cohort B1.5 or B1.0 experiences Grade 3 or greater local or systemic toxicities by week 4, that total dose of 4.5 or 3.0 x 1011 vp/day will be accepted for further clinical assessment. All three injected lesions and 1-2 non-injected lesions will be excised after 6 months.
Cohort C may be designed based on the results observed in Cohorts A and B with the agreement of the Protocol Steering Committee. If a total dose >4.5 x 1011 vp/day of injection ASN-002 on any single day or more than 3 weekly injections are to be administered, a formal amendment to the Protocol must be approved before accrual to Cohort C is permitted.
Each cohort will be assessed for safety, dose escalation and possible cohort expansion as described above. The week 4 assessment of toxicity and apparent efficacy of the first 3 subjects in each cohort will be used to determine the need to increase the size of that cohort to 6 subjects. Cohorts will be assessed clinically at 1, 2, 3 and 4 months. Treated tumors will be resected at 6 months, based on observations in the ongoing Australia trial study that inflammation persisting at 16 weeks could not be reliably distinguished from residual tumor. The 1st and 3rd secondary endpoints, histological clearance of injected and non-injected lesions, will be assessed by the Pathology Department of each clinical site. Representative slides will be submitted for possible central review to be performed at the discretion of Ascend. Each participant will also be seen one month after tumor resection to assess healing and post-surgical results Each subject may be evaluated on the 7 month visit for a second cycle of 3 weekly ASN-002 injections into new or previously untreated BCC lesions at a dose accepted for further clinical assessment. Subjects who receive a second cycle will be followed for 6 months as before, but lesion excision will be at the discretion of the investigator.
In the event study subjects in any Cohort do not proceed to histological confirmation of response per protocol, they may be replaced as long as the reason for not proceeding to histological confirmation of response per protocol was not investigational product related adverse events and so long as the Protocol Steering Committee concurs with the Sponsor that no limiting safety issues have been identified.
Depending on results, and at the discretion of the Sponsor and the Protocol Steering Committee, one Cohort may be expanded to a total of 24 subjects so long as no more than one of six subjects already included at that dose and schedule of ASN-002 experienced Grade 3 or greater local or systemic toxicities. The selection of the cohort to be expanded will be based on favorable response data from the subjects already included at that dose and schedule of ASN-002,
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Sequential
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- This is a dose escalation study to determine the safety and efficacy of ASN-002 in treatment of BCCs in BCNS patients.
| Arm | Type | Receives |
|---|---|---|
| Cohort A | Experimental | Biological: ASN-002Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 4 BCCs, weekly x 3, i.e. weeks 1, 2, and 3 |
| Cohort B 1.5 | Experimental | Biological: ASN-002Subjects with 4 or more lesions will receive 1.5 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3 |
| Cohort B 1.0 | Experimental | Biological: ASN-002Subjects with 4 or more lesions will receive 1.0 x 10^11 vp/injection of ASN-002 into each of 3 BCCs, weekly x 3, i.e. weeks 1, 2, and 3 |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (16 listed)
- Must satisfy established criteria for the diagnosis of BCNS (Section 1.1.2, Table 1).
- Must have at least 4 target lesions, clinically consistent with BCC.
- Up to 6 target lesions, including each of the 3 or 4 to-be-injected lesions and 1 or 2 non-injected lesions must be biopsied.
- At least 3 target lesions, 2 to be injected and one to be non-injected, must be biopsy proven BCC per criteria in Synopsis Table 3: Modified Criteria for Low Risk BCC in BCNS Patients
- Removal of < 25% of the area of the tumor by initial biopsy performed within 12 weeks before screening visit. A 2mm punch biopsy is recommended for histological confirmation of BCC.
Key exclusion criteria (19 listed)
- Target tumor biopsy shows evidence of:
- Eastern Cooperative Oncology Group (ECOG) performance status > 2.
- Known or suspected metastatic disease.
- Female participants must be non-lactating and non-pregnant.
- Clinically active or uncontrolled skin disease that would interfere with evaluation of the area surrounding the target tumor (e.g. eczema, unstable psoriasis, xeroderma pigmentosa).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ASN-002ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity. | Biological | Cohort A, Cohort B 1.0, Cohort B 1.5 |
Primary outcome
Safety of ASN-002 will be studied in terms of AEs reported in individuals with Basal Cell Nevus Syndrome (BCNS) receiving ASN-002 using CTCAE 4.03.
Time frame: The assessment will be conducted at every visit after first dose, week1, week2, week 3, Months1, 2, 3, 4 and at Month 6.
Clinical safety will assessed in terms of changes in vital signs, AEs, serious AEs (SAEs), laboratory abnormalities and withdrawals from study. Local skin and injection site reactions will be assessed in detail scoring erythema, ulceration, pain and overall severity as none, mild, moderate or severe using protocol-specific modifications of the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
6 secondary outcomes
Treatment efficacy in term of percentage of histological cure of BCC lesions at 6 months
Time frame: 6 months from baseline
Clinical changes in BCCs after treatment with ASN-002 in- terms of change in lesion size (mm)
Time frame: 6 months from baseline.
The systemic effect of ASN-002 will be assessed for non-injected lesions by studying the change in lesion size from baseline to end of the study.
Time frame: 6 months from baseline
The safety in terms of the AEs reported (using CTCAE 4.03) after 6 months from first dose in retreatment cycle
Time frame: 6 months
The systemic effect of ASN-002 will be assessed for non-injected lesions by studying the rate of histological clearance after 6 months of first dose.
Time frame: 6 months from baseline
The efficacy will be assessed in terms of change in lesion size (mm) after 6 months from first dose in retreatment cycle
Time frame: 6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Feb 2023.
- Individual participant dataSharing planned: Undecided. The decision will be taken in due course of time.
Related trials for Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 2
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Amyloidosis, Basal Cell Carcinoma
RecruitingObservational study
Qualitative Study in Patients With Genodermatoses and Healthcare Professionals on Reproductive Counselling
Quality of Life, Ichthyosis
Enrolling by invitationObservational study
Reproductive Options in Inherited Skin Diseases
Ichthyosis, Palmoplantar Keratoses
RecruitingObservational study
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clement Leong study chair
Ascend Biopharmaceuticals Ltd
Anna Bar principal investigator
Oregon Health and Science University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing ASN-002 in people with Basal Cell Carcinoma in Basal Cell Nevus Syndrome, run by Ascend Biopharmaceuticals Ltd at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 16 inclusion and 19 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 6 Feb 2023. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety of ASN-002 will be studied in terms of AEs reported in individuals with Basal Cell Nevus Syndrome (BCNS) receiving ASN-002 using CTCAE 4.03. (time frame: The assessment will be conducted at every visit after first dose, week1, week2, week 3, Months1, 2, 3, 4 and at Month 6.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Feb 2023.